NEW YORK (360Dx) – Becton Dickinson announced this week an early access program for its BD Resolve single-cell gene expression platform that captures and analyzes "hundreds to tens of thousands of individual cells in a broad range of sizes and types."

The platform includes reagents that can analyze the whole transcriptome and targeted or custom-designed gene-specific panels, BD said, and noted that it's possible to improve data accuracy and reduce sequencing costs by pairing the platform with the firm's Facsmelody flow cytometer for cell sorting and enrichment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.